Abstract
Abstract
Background
Pembrolizumab is superior to chemotherapy as a first-line treatment for patients with mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer (CRC), with a significant long-term survival benefit according to the KEYNOTE-177 trial. The current study aimed to determine whether pembrolizumab is a cost-effective treatment for patients with dMMR/MSI-H advanced or metastatic CRC in China.
Methods
A partitioned survival model (PSM) was developed to simulate patients with dMMR/MSI-H advanced or metastatic CRC based on progression-free survival (PFS), progressive disease (PD) and death. The model was designed using a lifetime horizon, a 6-week cycle, and a 5% discount rate. The patients in the model had metastatic dMMR/MSI-H CRC and had not previously received treatment; these characteristics were similar to those of patients in KEYNOTE-177, a phase 3, open-label randomized clinical trial. The health outcomes and utilities were based on the KEYNOTE-177 trial and published data, respectively. Costs were calculated based on local charges (2022) and published literature. A treatment was deemed cost-effective in China if the incremental cost-effectiveness ratio (ICER) value was less than U.S.$38,142.56 per quality-adjusted life-year (QALY). The robustness of the results was assessed via one-way deterministic and probabilistic sensitivity analyses.
Results
Baseline analysis revealed that pembrolizumab provided an additional 2.58 QALYs (3.00 life-year) at an incremental cost of U.S.$78,286.04, resulting in an ICER of U.S.$30,330.15 per QALY, which was below the willingness-to-pay threshold of U.S.$38,142.56 per QALY. When the patient assistance program (PAP) was considered, the ICER became U.S.$1,730.67 per QALY, manifesting absolute cost-effectiveness. The results of sensitivity analyses demonstrated that pembrolizumab was cost-effective in most cases.
Conclusions
Pembrolizumab is a cost-effective first-line treatment for dMMR/MSI-H advanced or metastatic CRC patients in China, especially considering the PAP.
Funder
Zhejiang Pharmaceutical Association
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22.
2. Chang SBY, Pu HQ, et al. Disease burden of colorectal cancer in Jinchang cohor. Chin J Epidemiol. 2016;37(3):325–8.
3. Huang H, Shi JF, Guo LW, et al. Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China:a hospital-based, multicenter, cross-sectional survey. Chin J Cancer. 2017;36(1):41.
4. Liu CCHH, Shi JF, et al. Economic burden of colorectal cancer in China from 1996 to 2015:a systematic review. China Cancer. 2017;26(11):859–67.
5. Wang H, Cao MD, Liu CC, et al. Disease burden of colorectal cancer in China: any changes in recent years? Chin J Epidemiol. 2020;41(10):1633–42.